Immune Therapeutics, Inc.
IMUN · OTC
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $14 | $153 | $126 | $336 |
| G&A Expenses | $0 | $586 | $760 | $2,500 |
| SG&A Expenses | $1,149 | $586 | $760 | $2,500 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $1 | $2 |
| Operating Expenses | $1,163 | $738 | $887 | $2,838 |
| Operating Income | -$1,163 | -$738 | -$887 | -$2,838 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$2,373 | $4,324 | $2,476 | -$559 |
| Pre-Tax Income | -$3,536 | $3,586 | $1,589 | -$3,397 |
| Tax Expense | $2,252 | $0 | $480 | $1,276 |
| Net Income | -$5,788 | $3,586 | $1,109 | -$4,673 |
| % Margin | – | – | – | – |
| EPS | -0.16 | 7.41 | 2.4 | -10.44 |
| % Growth | -102.2% | 208.8% | 123% | – |
| EPS Diluted | -0.16 | 0.38 | 2.4 | -10.44 |
| Weighted Avg Shares Out | 36,290 | 484 | 461 | 448 |
| Weighted Avg Shares Out Dil | 36,290 | 9,394 | 461 | 448 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $120 | $211 | $480 | $894 |
| Depreciation & Amortization | $520 | $2,645 | -$172 | $384 |
| EBITDA | -$643 | $1,907 | -$1,060 | -$2,454 |
| % Margin | – | – | – | – |